BOYALIFE BIOPHARMA LTD
BOYALIFE BIOPHARMA LTD (China) holds 1 active US FDA Type II Drug Master File. No FDA recall, Warning Letter or Form 483 record is linked to it, which is not proof that none exists.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “BOYALIFE BIOPHARMA LTD: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/boyalife-biopharma-ltd
Overview
BOYALIFE BIOPHARMA LTD is an active pharmaceutical ingredient (API) supplier with 1 active FDA Type II Drug Master File, covering HUMAN UMBILICAL CORD WHARTONS JELLY MESENCHYMAL STEM CELL EXOSOMES.
API / Drug Master Files
BOYALIFE BIOPHARMA LTD holds 1 active (1 total) FDA Type II Drug Master File. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- HUMAN UMBILICAL CORD WHARTONS JELLY MESENCHYMAL STEM CELL EXOSOMESActive2024-12-01
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to BOYALIFE BIOPHARMA LTD in our records. Events are linked by company name and identifier, so this is not proof that none exist; check the FDA's own databases before relying on it.
Is this BOYALIFE BIOPHARMA LTD?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Related companies
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.